Sensus Healthcare, Inc. (NASDAQ:SRTS) insider Kalman Fishman sold 5,378 shares of the company’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $6.00, for a total transaction of $32,268.00. Following the completion of the transaction, the insider now owns 990,845 shares in the company, valued at $5,945,070. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Sensus Healthcare, Inc. (NASDAQ SRTS) traded down 0.17% on Friday, hitting $5.99. 27,123 shares of the stock were exchanged. The stock’s 50 day moving average price is $4.48 and its 200 day moving average price is $4.31. The firm’s market cap is $80.79 million. Sensus Healthcare, Inc. has a 52-week low of $3.38 and a 52-week high of $6.50.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings data on Thursday, August 3rd. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.08. The company had revenue of $4.97 million for the quarter, compared to the consensus estimate of $4.50 million. Sensus Healthcare had a negative return on equity of 16.40% and a negative net margin of 13.31%. Equities research analysts forecast that Sensus Healthcare, Inc. will post ($0.33) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/25/insider-selling-sensus-healthcare-inc-srts-insider-sells-5378-shares-of-stock.html.

A number of research analysts have recently commented on SRTS shares. Maxim Group started coverage on shares of Sensus Healthcare in a report on Tuesday, June 6th. They issued a “buy” rating and a $6.50 price target on the stock. Zacks Investment Research cut shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a report on Thursday, May 11th.

An institutional investor recently bought a new position in Sensus Healthcare stock. B. Riley Financial Inc. bought a new stake in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 104,794 shares of the company’s stock, valued at approximately $421,000. B. Riley Financial Inc. owned approximately 0.77% of Sensus Healthcare at the end of the most recent quarter. Institutional investors own 12.60% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, formerly Sensus Healthcare, LLC, is a manufacturer of superficial radiation therapy devices. The Company designs, manufactures and markets medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy.

Receive News & Stock Ratings for Sensus Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare Inc. and related stocks with our FREE daily email newsletter.